Women’s health company Organon (OGN), which was spun-off from Merck (MRK), has completed the acquisition of commercial-stage medical device company Alydia Health. The …
Nektar Therapeutics reported a better-than-expected loss in the fourth quarter but lagged analysts’ expectations for revenues. Shares of the biopharmaceutical company dropped almost …
Merck & Company agreed to snap up Pandion Therapeutics, a clinical-stage biotechnology company, in a deal worth $1.85 billion.
Merck & Co. has decided to stop the development of its two COVID-19 vaccine candidates following “inferior” immune responses.
Merck & Co has entered into a definitive agreement to snap up all outstanding shares of VelosBio for $2.75 billion in cash, in …
Sanofi (SNYNF) has entered into an agreement with Merck to conduct a Phase 2 clinical trial to evaluate the safety, pharmacokinetics, and preliminary …
With COVID-19 cases continuing to surge, the attention of the whole world is currently on pharma companies developing potential treatments and vaccines for …
Merck raised its 2020 adjusted profit outlook as the pharma giant is witnessing high demand for its cancer drug Keytruda as well as …
Merck (MRK) has announced that the U.S.
AstraZeneca announced that its Lynparza drug has been recommended for marketing authorization in the European Union (EU) for patients with metastatic prostate cancer (mCRPC) …